tiprankstipranks
Advertisement
Advertisement

Starcoin Faces Prolonged Share Suspension After HKEX Review Cites Weak Operations, Heavy Liabilities

Story Highlights
  • Hong Kong’s Listing Review Committee upheld Starcoin’s share suspension, citing insufficient operations and asset support for a continued listing.
  • Regulators flagged stalled oral insulin trials, heavy net current liabilities and reliance on a major shareholder, underscoring heightened risk for investors.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Starcoin Faces Prolonged Share Suspension After HKEX Review Cites Weak Operations, Heavy Liabilities

Meet Samuel – Your Personal Investing Prophet

Innovative Pharmaceutical Biotech ( (HK:0399) ) has shared an announcement.

Starcoin Group Limited has been notified by the Listing Review Committee of the Hong Kong Stock Exchange that its decision to suspend trading in the company’s shares will be upheld. The committee found that Starcoin had failed to maintain sufficient operations and assets of adequate value to justify a continued listing under the exchange’s rules.

The committee highlighted that the company’s core oral insulin project has made no material clinical progress since 2014 and lacks a concrete, credible plan to achieve its targeted completion date, amid significant regulatory uncertainties. It also noted Starcoin’s heavy net current liabilities, dependence on a major shareholder for financing, and unproven revenue-generating capacity in its trading, health supplement and blockchain businesses, despite sizeable intangible assets on its balance sheet.

Further concern centered on HK$1 billion in convertible bonds owed to Extrawell Pharmaceutical Holdings, where a proposed maturity extension to 2030 remains contingent on multi‑party approvals. Taken together, these operational and financial weaknesses led the committee to conclude that Starcoin’s shares should remain suspended, reinforcing the company’s precarious position and signaling heightened risk for investors and other stakeholders.

More about Innovative Pharmaceutical Biotech

Starcoin Group Limited, formerly Innovative Pharmaceutical Biotech Limited, is a Hong Kong-listed company incorporated in the Cayman Islands and continued in Bermuda. The group has focused on developing an oral insulin product and has also pursued trading, health supplements and blockchain-related activities, though these ancillary businesses remain small in scale and lack a strong revenue track record.

Average Trading Volume: 47,673,353

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$367.4M

For a thorough assessment of 0399 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1